Skip to content

Cannabis: all studies

Page 226 of 289: studies 2,251 to 2,260 of 2,882, newest first. Back to the cannabis overview

Research

Effects of the Acute and Chronic Administration of Cannabidiol on Cognition in Humans and Animals: A Systematic Review.

Cannabis and Cannabinoid Research December 2023 Ana Julia de Lima Bomfim, Stefany Mirrelle Fávero Zuze, Daiene de Morais Fabrício et al.

Introduction: The effects of cannabidiol (CBD) on cognition has been investigated in recent years to determine the therapeutic potential of this cannabinoid for a broad gamut of medical conditions, including neuropsychiatric disorders. The aim of the present study was to perform a systematic review of studies that analyzed the effects of the acute and chronic administration of CBD on cognition...

Public Interest in Psilocybin and Psychedelic Therapy in the Context of the COVID-19 Pandemic: Google Trends Analysis

JMIR Formative Research November 28, 2023 George Danias, Jacob Appel 13 citations

Background Psychedelic substances have demonstrated promise in the treatment of depression, anxiety, and substance use disorders. Significant media coverage has been dedicated to psychedelic medicine, but it is unclear whether the public associates psilocybin with its potential therapeutic benefits. The COVID-19 pandemic led to an increase in depression, anxiety, and substance abuse in the...

DOI: 10.2196/43850 (opens in new tab) Anxiety Depression Google trends Antidepressant +9

A case of incubus phenomenon

European Psychiatry November 17, 2023 L. Tjokrodipo, A. Sneep, P. Michielsen

Introduction The incubus phenomenon is a paroxysmal sleep-related disorder in which patients experience sleep paralysis and compound hallucinations. The symptoms of this phenomenon contain: sensed presence, fear, visual and auditory hallucinations, unusual body experiences such as out-of-body experience and feelings of floating/paralysis, experiencing a pressure on the thorax, difficulties...

Chronic psychosis associated with new hallucinogenic drug 25I-NBOMe

European Psychiatry October 23, 2023 O. Martin-Santiago, G. Guerra-Valera, C. Alario-Ruiz et al.

Introduction The presence of perceptual disturbances and psychotic symptoms associated with substance abuse are widely known. While the abuse of substances is becoming more widespread, there is a general perception that their use entails fewer risks. 25I-NBOMe is a recently introduced hallucinogenic drug producing visual hallucinations and euphoria. Although people consume it like LSD, its...

Subtle Structural Modification of a Synthetic Cannabinoid Receptor Agonist Drastically Increases its Efficacy at the CB1 Receptor

ACS Chemical Neuroscience October 17, 2023 Hideaki Yano, Rezvan Chitsazi, Christopher Lucaj et al. 12 citations

The emergence of synthetic cannabinoid receptor agonists (SCRAs) as illicit psychoactive substances has posed considerable public health risks, including fatalities. Many SCRAs exhibit much higher efficacy and potency compared with the phytocannabinoid Δ 9 -tetrahydrocannabinol (THC) at the cannabinoid receptor 1 (CB1R), leading to dramatic differences in signaling levels that can be toxic. In...

DOI: 10.1021/acschemneuro.3c00530 (opens in new tab) Cannabinoid receptor agonists Rimonabant Pharmacology Biochemistry

PPARα and PPARγ are expressed in midbrain dopamine neurons and modulate dopamine- and cannabinoid-mediated behavior in mice.

Molecular Psychiatry October 2023 Briana J. Hempel, Madeline Crissman, Sruti Pari et al.

Peroxisome proliferator-activated receptors (PPARs) are a family of nuclear receptors that regulate gene expression. Δ9-tetrahydrocannabinol (Δ9-THC) is a PPARγ agonist and some endocannabinoids are natural activators of PPARα and PPARγ. However, little is known regarding their cellular distributions in the brain and functional roles in cannabinoid action. Here, we first used RNAscope in situ...

Substance use in sexual minority youth: prevalence in an urban cohort.

Child and Adolescent Psychiatry and Mental Health September 16, 2023 Florian Vock, Lydia Johnson-Ferguson, Laura Bechtiger et al. 3 citations

Little comparative data on substance use (SU) between sexual minority youth (SMY) and heterosexual youth (HET) is available. This study compares the prevalence of SU in an urban cohort between SMY and HET and evaluates demographic and psychosocial predictors of SU. Data came from a prospective-longitudinal cohort study in an urban setting (N = 1297). SU and psychosocial variables such as...

Psychedelic Commercialization: A Wide-Spanning Overview of the Emerging Psychedelic Industry.

Psychedelic Medicine September 13, 2023 Jacob S. Aday, Brian S. Barnett, Dan Grossman et al. 56 citations

Background: In the wake of positive clinical trial outcomes of psychedelic-assisted psychotherapy for the treatment of various psychiatric disorders, there has been an influx of financial investment into psychedelic drug development from the pharmaceutical and biotech sectors. Psychedelics are now a multibillion dollar industry, with hundreds of companies that are seeking to commercialize...

DOI: 10.1089/psymed.2023.0013 (opens in new tab) Full text (opens in new tab) Psychedelics Pharmaceutical-industry Mental-health-treatment Indigenous-medicine +1

Perturbation of 3D nuclear architecture, epigenomic dysregulation and aging, and cannabinoid synaptopathy reconfigures conceptualization of cannabinoid pathophysiology: part 1–aging and epigenomics

Frontiers in Psychiatry September 5, 2023 Albert Stuart Reece, Gary Kenneth Hulse 1 citation

Much recent attention has been directed toward the spatial organization of the cell nucleus and the manner in which three-dimensional topologically associated domains and transcription factories are epigenetically coordinated to precisely bring enhancers into close proximity with promoters to control gene expression. Twenty lines of evidence robustly implicate cannabinoid exposure with...

EVALUATION OF THE THERAPEUTIC NEUROTOXIC EFFECTS OF THE USE OF AYAHUASCA BY DEPRESSIVE PATIENTS

Revista Contemporânea September 5, 2023 Catarina Rodrigues Damasceno Murucci, Rita de Cássia Ramos Queiroz de Freitas, Grazielly Ribeiro Viana et al.

Ayahuasca is a tea used in original indigenous rituals with the aim of expanding the mind and consciousness. Some studies have pointed to Ayahuasca as a potent antidepressant with reduced side effects when compared to other conventional synthetic allopathic treatments. Over the years, tea has come to be known by both the popular community and the scientific community. The species used are...

DOI: 10.56083/rcv3n9-011 (opens in new tab) Ayahuasca Pharmacology Harmaline Traditional medicine +1